Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential

Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential

Deregulated activity of the Src tyrosine kinases leads to malignant transformation. Since the FDA approval of the tyrosine kinase inhibitor, imatinib, in 2001 for the treatment of chronic myeloid leukemia (CML), the number of these inhibitors together with Src tyrosine kinase inhibitors (STKIs) has...

Full description

Bibliographic Details
Main Authors: José Rivera-Torres, Esther San José
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Pharmacology
Subjects:
Src tyrosine kinase inhibitors
dasatinib
immunotherapy
LGLs
γδ T cells
senescence
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.01011/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.01011/full

Similar Items